X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc. to discover novel drug candidates by screening vast libraries of chemical compounds against high-value pharmaceutical targets. X-37 develops these novel drug candidates under an innovative LLC structure that allows simple and efficient sales or partnerships for individual development programs. The team at X-37 possesses extensive expertise in the selection of high-value pharmaceutical targets and pharmaceutical development.

X-37 has initiated five development programs in areas of high medical need including cancer, autoimmune diseases, and coagulation disorders. The team at X-37 will advance drug candidates identified via AtomNet through initial screening assays and pre-clinical testing with a goal to begin human clinical trials in 2022.

Company Information

April 20, 2022